What contraindication is associated with using MAA for treatment?

When considering the use of microaggregated albumin (MAA) in treatment, particularly in the context of trans arterial radioembolization (TARE) or other similar interventions, it is essential to be aware of potential contraindications that can affect patient safety and treatment efficacy. One significant contraindication is poor renal function.

The use of MAA is often associated with the risk of increased radiation exposure to the kidneys, especially when there is compromised renal function. The kidneys are responsible for filtering blood and excreting waste, and poor renal function can lead to a decreased ability to process and eliminate substances, including those involved in radioembolization procedures. If MAA accumulates in the kidneys, it can cause radiological harm, increased toxicity, or even lead to acute renal failure. Thus, patients with pre-existing renal insufficiency are often advised against the use of MAA due to these risks.

In contrast, when examining the other potential contraindications: hepatic malignancies are frequently the target of MAA treatments; a patent portal vein is generally a necessary anatomical feature for the appropriate delivery of treatment; and congenital liver anomalies can often be managed on a case-by-case basis, depending on how they affect vascular access or treatment delivery.